AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00690651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard mobilization
Description: this group will rest in bed with their leg elevated above their heart for 48 hours post surgery to ankle fracture and will then mobilize with physiotherapist with aim to discharge home.
Study NCT03065660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone, Oral, 200 Mg
Description: The Investigational Medicinal Product (IMP) is a single dose of 200mg mifepristone to be taken orally after confirmation of missed miscarriage by pelvic ultrasound scan.
Study NCT03065660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The placebo will be an oral tablet in the same form as the IMP, and identical in appearance.
Study NCT03043781 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous epidural infusion
Description: Continuous infusion, 5 ml/h
Study NCT00985920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues.
Study NCT03043781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent epidural bolus
Description: Intermittent bolus 5 ml every hour
Study NCT01952951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine Oxaliplatin
Description: after completion of chemoradiation, two cycles of capecitabine (850mg/m2 twice daily from D1 evening to D15 morning) and oxaliplatin (100mg/m2 on D1) will be administered every 3 weeks.
Study NCT01952951 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: pelvic radiation capecitabine 5-fluorouracil
Description: 50.4Gy of pelvic radiation with capecitabine or 5-fluorouracil
Study NCT03962673 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: NB-UVB light exposure
Description: Participants are exposed to three low dose Narrow Band UVB light.
Study NCT02605395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDIAZOLE 20mg DR tabs
Description: IDIAZOLE 20mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
Study NCT02605395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARIET 20 mg DR tabs
Description: PARIET 20 mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg rabeprazole sodium.
Study NCT00383656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: 75 ng/kg GnRH IV
Study NCT00383656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pump
Description: portable, infusion pump for GnRH
Study NCT00985920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues.
Study NCT01772030 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Use of the Achieve catheter followed by ICE-guided mapping catheter
Study NCT03310697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of blood and urine samples
Description: For each child, a toxicological screening will be carried out on the blood and urine for the research of proconvulsive molecules by conventional technique on the one hand and by gas chromatography coupled with a mass spectrograph on the other hand.
Study NCT03310697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination
Description: The other clinical data, any other biological samples or additional examinations are done under the opinion of the clinician or the neuropediatrics.
Study NCT03447717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiGait
Description: implanted device for peroneal nerve stimulation
Study NCT00881322 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BC-130 (Gas Defense)
Description: Product Dosing:~Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)~Gas Defense Serving Size: 1 tablet Active Ingredients: B. Coagulans, Enzyme Blend (Cellulase - Trichoderma longibrachiatum, Cellulase - Aspergillus niger, Hemicellulase, Alpha Galactosidase, Invertase) Inactive Ingredients: vegetable capsule, Magnesium Stearate, Silicon Dioxide, Maltodextrin Contains: Wheat, Fish.
Study NCT00881322 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Product Dosing:~Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)~Placebo - matched in size and color to the active product Inactive Ingredients: microcrystalline cellulose, FD\&C yellow #5 Lake, FD\&C blue #1 Lake, FD\&C red #46 Lake and vegetable capsule
Study NCT05867095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical navigation
Description: Patients will be operated with assistance of a navigation system
Study NCT05867095 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional
Description: Patients will be operated using the conventional technique
Study NCT01216566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occiflex Device
Description: This device is a computerized robotic platform that allows continuous mobilization of the cervical spine in a three dimensional space. The patients undergoes biweekly 20 minute therapeutic session for 6 weeks
Study NCT00086996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Before surgery: 180 mg/m2/day by 24-hour infusion days 8 through 43. After surgery:180 mg/m2/day by 24-hour infusion days 1 through 36.
Study NCT00086996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Before surgery: 85 mg/m2 by 2-hour IV infusion days 1, 15, and 29. After surgery: 85 mg/m2 by 2-hour IV infusion days 1, 15, and 29.
Study NCT00086996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: The surgical technique will depend upon the location and extent of tumor and individual surgeon preference.
Study NCT00086996 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Starting Day 8, patients will be treated 5 days/week at 180 centigray (cGy)/day times 25 fractions to a total dose of 4,500 cGy.
Study NCT01798212 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: endoscopic full thickness plication
Study NCT01814462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 6 months CPAP
Study NCT01952951 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: pelvic radiation capecitabine 5-fluorouracil
Description: 50.4Gy of pelvic radiation with capecitabine or 5-fluorouracil
Study NCT02251639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Participant completes a short questionnaire regarding their awareness of oral cancer and risk factors.
Study NCT02251639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POS + PS2 + VELscope
Description: Oral cavity examined with one or more of the widefield imaging devices, such as the VELscope and/or PS2 device.
Study NCT03656783 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Biktarvy
Description: Open-label, multicenter, single-arm study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Abacavir/Lamivudine/Dolutegravir (ABC/3TC/DTG) to the Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV-Infected Adult Subjects
Study NCT03148886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PA intervention
Description: The program is individualized according to age, fitness level, place of residence, access to adapted specific training group or associations, PA preferences and wishes of each participant. Patients are informed of the recommendations in terms of PA, and the target of 150min per week in order to maintain health benefits. Patients are asked to walk at least 30 minutes per day and increase their activities into daily routine. Several individual strategies are established with the patients to attain their objectives and increase their daily life PA.~Withings® PA trackers have been used to provide an incentive effect to increase PA, to measure the number of steps per day and make people think about their PA. Patients wore a Withings Go® wristband PA tracker throughout the whole study and had in real time a feedback on their number of steps per day.~A 7 mL blood sample is collected at baseline (D1) and at the end of the 6-month study (M6) for the biological study.
Study NCT02251639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral Brush Biopsy
Description: If abnormal areas found, a small brush is pressed against an area inside mouth, and turned 5-10 times. The areas that could be biopsied include gums, tongue, roof of mouth, bottom of mouth, or the inside of cheeks.
Study NCT04150887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cusatuzumab
Description: Cusatuzumab will be administered as a dose of 10mg/kg or 20mg/kg intravenously.
Study NCT04150887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered 75 mg/m\^2 subcutaneously or intravenously.
Study NCT04150887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally and the dose will ramp-up to 400 mg.
Study NCT01974739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochloorthiazide
Study NCT01974739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03268421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fibromyalgia Integrative Training for Teens
Description: This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
Study NCT03268421 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
Study NCT03268421 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Graded Aerobic Exercise
Description: This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
Study NCT03140358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine sulfate 0.01%
Description: Atropine 0.01%
Study NCT03140358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04540510 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OPEP therapy
Description: Oscillatory Positive Expiratory Pressure therapy
Study NCT04540510 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard pneumonia care
Study NCT02140255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Description: Administered orally. Dosed according to study step/participant's age/participant's weight.
Study NCT02140255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (LPV/r)
Description: Administered orally. Dosed according to study step and participant's age.
Study NCT02140255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Description: Administered orally. Dosed according to study step and participant's age.
Study NCT02140255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC01
Description: 40 mg/kg administered subcutaneously.
Study NCT02140255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG
Description: Administered orally. Dosed according to participant's weight.
Study NCT02140255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: 40 mg/kg administered subcutaneously.
Study NCT02550028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral levetiracetam
Description: Oral load of levetiracetam (50 mg/kg) following identification of EEG confirmed neonatal seizure.
Study NCT02550028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous phenobarbital
Description: Intravenous load of phenobarbital (20 mg/kg)following EEG confirmation of seizure activity load.
Study NCT04184687 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nanofractures
Description: anterior cruciate ligament reconstruction will be performed in combination with the nanofractures for the treatment of cartilaginous lesions
Study NCT04184687 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no treatment cartilaginous lesions
Description: patient undergoing to the anterior cruciate ligament reconstruction without treatment of the cartilaginous lesions
Study NCT02321293 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CurcuVIVA™
Description: 80 mg PO daily for 8 weeks with an option to reduce the dose based on individual tolerability
Study NCT02321293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine Kinase Inhibitor gefitinib (Iressa)
Description: 250 mg PO daily until progression
Study NCT02321293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine Kinase Inhibitor erlotinib (Tarceva)
Description: 150 mg PO daily until progression
Study NCT01231555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 100 mg once daily
Description: 1x100 mg capsule plus matching placebo
Study NCT01231555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 200 mg once daily
Description: 2x100 mg capsules
Study NCT01231555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz 600 mg once daily
Description: 1x600mg tablet
Study NCT01126255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol propionate 0.05%
Description: Topical application, once daily about 2 g, during 12 weeks
Study NCT01126255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone 8%
Description: Topical application, once daily about 2 g, during 12 weeks
Study NCT02550158 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Educational program EDU-MICI
Study NCT02064088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 0,2 ml/kg of 0,2% levobupivacaine for small volume group
Description: Ultrasound guided administration of 0,2 ml/kg of 0,2% lévobupivacaine in the plane between the internal oblique and transversus abdominis muscles
Study NCT01097031 — intervention group
Intervention type: OTHER
Intervention: Infusion Intermittent
Study NCT01049945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV
Study NCT01049945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally
Study NCT01049945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally or IV
Study NCT04443595 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual-scopic pancreatic necrosectomy（DPN）
Description: Treatment of Acute Severe Pancreatitis with DPN
Study NCT02248675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I), an evidence-based insomnia treatment. In this study it will be delivered in four individual sessions.
Study NCT02064088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 0,4 ml/kg of 0,1% lévobupivacaine for high volume group
Description: Ultrasound guided administration of 0,4 ml/kg of 0,1% lévobupivacaine in the plane between the internal oblique and transversus abdominis muscles
Study NCT01475448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long distance training
Description: Long distance training during four months, 3 times per week
Study NCT01475448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking training
Description: Walking training during four months, three times per week
Study NCT02099981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminoguanidine
Study NCT02248675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAU
Description: Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.
Study NCT02248675 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.
Study NCT02911662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Cephalexin will be prescribed for women with a positive urine culture but no symptoms of urinary tract infection.
Study NCT02911662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: Cephalexin will be prescribed for women with a positive urine culture but no symptoms of urinary tract infection.
Study NCT02911662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Description: Macrobid will be prescribed for women allergic to penicillin with a positive urine culture but no symptoms of urinary tract infection.
Study NCT02911662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin
Description: Macrobid will be prescribed for women allergic to penicillin with a positive urine culture but no symptoms of urinary tract infection.
Study NCT03478748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental health education
Description: Anticipatory guidance given to mothers to promote their children's oral health.
Study NCT03478748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dental health education
Description: Anticipatory guidance given to mothers to promote their children's oral health.
Study NCT03607097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Secondary prevention program for drug related problems
Description: The interventions consists of three stages: 1) actions aimed at improving the chronic prescription of the patient, 2) actions aimed at improving the therapeutic adherence and 3) actions aimed at improving the assistance healthcare levels coordination
Study NCT01033565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natrol
Description: 5mg of sustained released melatonin. One tablet given 30 minutes prior to bedtime.
Study NCT03101995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 300 mg/m2, prepared in 0.5 liters of sodium chloride 0.9%, IV administered in 30 minutes weekly for a maximum of 6 weeks.~Radiotherapy will start the first week, or as soon as the blood count is normal or the patient has recovered after blood transfusion. Radiotherapy will be applied, using an external beam releasing 40-50.4 Gy in 20-28 fractions: 1.8 Gy/day for 5 days/week, during 4 to 6 weeks.~Intracavitary brachytherapy will be added to reach a total EQD2 dosage (α/β=10) of 78-86 Gy.
Study NCT03503578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Subjects will received sevoflurane for approximately 60 minutes.
Study NCT03503578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Subjects will received sevoflurane and ketamine for approximately 60 minutes.
Study NCT00076934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG2077 (CTLA4-IgG4m)
Description: RG2077